Skip to main content

Table 4 Dose reductions and discontinuations

From: Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma

Characteristic PTCL (N = 131) CTCL (N = 102)
Dose reduction due to adverse events, n (%) 14 (11) 14 (14)
Dose interruptions due to adverse events, n (%) 61 (47) 35 (34)
Discontinuation, n (%)   
 Progressive disease 78 (60) 22 (22)
 Adverse event 22 (17) 24 (24)
 Adverse event related to romidepsin treatment 11 (8) 17 (17)
 Othera 7 (5) 26 (26)
  1. CTCL, cutaneous T-cell lymphoma; PTCL, peripheral T-cell lymphoma.
  2. aMost often refers to withdrawal of consent.